Foundation for Sarcoidosis Research Launches Say Sarcoidosis Campaign to Shed Light on the 1.2 Million People Impacted by Sarcoidosis for April’s Awareness Month
01 avr. 2024 07h41 HE
|
Foundation for Sarcoidosis Research
FSR Launches Say Sarcoidosis campaign for April's Awareness Month
26 Patient Volunteer Leaders Attend the Foundation for Sarcoidosis Research Global Sarcoidosis Clinic Alliance Volunteer Patient Leadership Advanced Training Conference held at Cleveland Clinic
27 mars 2024 06h41 HE
|
Foundation for Sarcoidosis Research
26 Patient Volunteer Leaders joined the Foundation for Sarcoidosis Research at Cleveland Clinic for the Leadership Advanced Training Conference
Foundation for Sarcoidosis Research Partners to Host 30 Volunteer Patient Leaders at Unique In-Person Training at Cleveland Clinic
01 mars 2024 10h35 HE
|
Foundation for Sarcoidosis Research
FSR to host in-person training of Volunteer Patient Leaders from around the United States at Cleveland Clinic.
aTyr Pharma Announces Expanded Access Program (EAP) for EFZO-FIT™ Clinical Trial Participants
21 févr. 2024 08h00 HE
|
aTyr Pharma, Inc.
Tyr Pharma Announces Expanded Access Program (EAP) for EFZO-FIT™ Clinical Trial Participants
Tricha Shivas Promoted to Chief of Staff and Strategy at Foundation for Sarcoidosis Research
15 févr. 2024 06h23 HE
|
Foundation for Sarcoidosis Research
The Foundation for Sarcoidosis Research (FSR) proudly announces the promotion of Tricha Shivas to Chief of Staff and Strategy.
aTyr Pharma to Present Posters Highlighting Importance of Neuropilin-2 in Immune Regulation at Keystone Symposia on Myeloid Cell Diversity
29 janv. 2024 08h00 HE
|
aTyr Pharma, Inc.
aTyr Pharma to present posters on the importance of Neuropilin-2 in immune regulation at the Keystone Symposia on Myeloid Cell Diversity.
aTyr Pharma Announces Howard University President Emeritus Dr. Wayne A. I. Frederick as Advisor
18 janv. 2024 08h00 HE
|
aTyr Pharma, Inc.
aTyr Pharma Announces Howard University President Emeritus Dr. Wayne A. I. Frederick as Advisor for efzofitimod program in interstitial lung disease (ILD).
The Foundation for Sarcoidosis Research (FSR) awards $100,000 in support of cardiac sarcoidosis
18 déc. 2023 15h41 HE
|
Foundation for Sarcoidosis Research
The Foundation for Sarcoidosis Research (FSR) awards $100,000 in support of cardiac sarcoidosis.
Foundation for Sarcoidosis Research Announces 3 New Members to the 40 Member FSR Global Sarcoidosis Clinic Alliance through its FSR-GSCA Capacity Building Grants
01 nov. 2023 11h26 HE
|
Foundation for Sarcoidosis Research
Foundation for Sarcoidosis Research announces three clinics that have been selected as members of FSR Global Sarcoidosis Clinic Alliance
Molecure Announces First Half 2023 Results – Significant Financial and Operating Momentum
29 sept. 2023 06h00 HE
|
Molecure
Molecure strategy update for 2023-2025 based on the development of a diversified portfolio of innovative research projects with the potential for breakthrough therapies for incurable diseasesCompleted...